论文信息 - The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts) - 字舞流文

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts)

R. Figlin | C. Ryan | R. Bukowski | W. Stadler | J. Dutcher | J. Knox | J. Humphrey | Thomas E. Hutson | J. Kirshner | J. George